Loading...
•
Sep 30, 2023
PTC Therapeutics Q3 2023 Earnings Report
PTC Therapeutics reported third quarter 2023 financial results with total revenues of $197 million and provided regulatory updates for pipeline programs.
Key Takeaways
PTC Therapeutics reported total revenues of $196.6 million for the third quarter of 2023. The company finalized a strategic partnership with Royalty Pharma, strengthening its financial position. PTC is progressing with regulatory submissions for its pipeline programs, including sepiapterin in PKU, and continues enrollment in the PIVOT-HD study for PTC518 for Huntington’s disease.
Total revenues for Q3 2023 were $196.6 million.
DMD franchise revenue was $136 million in Q3 2023.
PTC finalized a strategic partnership with Royalty Pharma, acquiring additional royalties of Evrysdi for $1.0 billion upfront.
PTC expects to submit an MAA to the EMA for sepiapterin for the treatment of PKU in the first half of 2024.
PTC Therapeutics
PTC Therapeutics
PTC Therapeutics Revenue by Segment
Revenue by Segment
Translarna Revenue
CapyFin.comEmflaza Revenue
CapyFin.comDMD Franchise Revenue
CapyFin.com Forward Guidance
PTC anticipates total revenues for full-year 2023 to be between $940 million and $1.0 billion. PTC anticipates net product revenue for the DMD franchise for full-year 2023 to be between $565 million and $595 million. PTC anticipates GAAP R&D and SG&A expenses for full-year 2023 to be between $915 million and $965 million. PTC anticipates Non-GAAP R&D and SG&A expenses for full year 2023 to be between $810 million and $860 million, excluding estimated non-cash stock-based compensation expense of $105 million. PTC expects to incur $37 million of one-time expenses related to the achievement of clinical success-based milestones from previous acquisitions and expenses associated with a rights exchange agreement, which have already been paid in equity and cash.
Revenue & Expenses
Visualization of income flow from segment revenue to net income